Bofanglutide (GZR18) vs. Semaglutide Phase III trial aims to evaluate weight loss and metabolic improvements in Latin American adults
Background
The global epidemic of overweight and obesity presents significant health challenges, increasing the risk of type 2 diabetes, cardiovascular disease, and other metabolic disorders. Current pharmacological interventions, including GLP-1 receptor agonists like semaglutide, have shown substantial efficacy in weight management and metabolic improvement. However, there remains a need for novel agents that offer improved efficacy, different dosing regimens, or enhanced tolerability profiles. This trial investigates Bofanglutide (GZR18), a potential new therapeutic, against the established semaglutide to address these gaps, particularly within a Latin American population.
Study Design
This multicenter, randomized, open-label, parallel-group Phase III clinical trial (BALANCE-OBS) is recruiting Latin American adults with overweight or obesity. Participants will be randomized to receive either Bofanglutide (GZR18) via subcutaneous injection every 2 weeks or Semaglutide once weekly via subcutaneous injection. The study duration includes a treatment period of 36 weeks, followed by a safety follow-up, totaling up to 40 weeks. All participants will adhere to standardized diet and physical activity recommendations. Primary endpoints include body weight reduction, with secondary endpoints assessing metabolic parameters, cardiovascular risk factors, and quality of life, alongside comprehensive safety and tolerability evaluations.
Results
This is an ongoing, recruiting Phase III clinical trial (NCT07150975), and specific efficacy and safety results are not yet available. The study aims to compare the body weight reduction, metabolic parameter improvements, cardiovascular risk factor modulation, and quality of life impacts of Bofanglutide (GZR18) against Semaglutide over 36 weeks of treatment. Safety and tolerability profiles will also be thoroughly assessed.
The primary objective is to determine if Bofanglutide (GZR18) reduces body weight after 36 weeks of treatment compared with Semaglutide.
Key Findings
- Results pending from this Phase III clinical trial.
Why It Matters
If Bofanglutide (GZR18) demonstrates superior or comparable efficacy with a favorable safety profile, it could offer a valuable new option for individuals managing overweight or obesity, particularly those seeking less frequent dosing (bi-weekly vs. weekly). This trial's focus on a Latin American population is crucial, as it addresses potential ethnic differences in treatment response and tolerability, which could inform more tailored clinical guidelines. A successful outcome could expand the therapeutic landscape for chronic weight management, potentially improving adherence and outcomes for a broader patient demographic. The results will be critical for understanding its place in the evolving treatment paradigm for metabolic health.
bofanglutide
semaglutide
obesity
overweight
weight-loss
clinical-trial